Amylyx Pharmaceuticals, Inc. (AMLX) — Stock Score Summary

Amylyx Pharmaceuticals, Inc. (AMLX) has a MoatMap StockRank of 32/100 based on Quality (34/100), Value (35/100), and Momentum (50/100) factor scores. The current signal is HOLD. Similar to other biotech firms, Amylyx Pharmaceuticals faces high R&D risks and regulatory hurdles, making it difficult to ascertain a durable moat or predictable cash flows consistent with the fund's quality compounding philosophy, and lacks a clear asymmetric macro tailwind.

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for neurodegenerative diseases, most notably Amyotrophic Lateral Sclerosis (ALS). The company's competitive moat is derived from its innovative drug candidates addressing high unmet medical needs and the regulatory approvals achieved for its key product in major markets. It focuses on improving the lives of patients with devastating neurological conditions.

Key Financial Metrics

Price$14.22
Market Cap$1.6B
P/E (Forward)-10.81
Price/Book5.56
Return on Equity-63.3%
Return on Invested Capital-49.5%
Debt/Equity2.06
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-72M

Amylyx Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Amylyx Pharmaceuticals, Inc.’s (AMLX) StockRank?
MoatMap’s StockRank for Amylyx Pharmaceuticals, Inc. (AMLX) is 32/100, with a Hold signal. It is a composite of Quality (34), Value (35), and Momentum (50) factor ranks across MoatMap’s 19,000+ stock universe.
Does Amylyx Pharmaceuticals, Inc. have an economic moat?
Amylyx Pharmaceuticals, Inc. (AMLX) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Amylyx Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Amylyx Pharmaceuticals, Inc. (AMLX) is Hold, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Amylyx Pharmaceuticals, Inc. in?
Amylyx Pharmaceuticals, Inc. (AMLX) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksAMLX deep dive reportAI ChampionsHow we score stocksSense-check another stock